Nykredit A/S’s Apogee Therapeutics APGE Stock Holding History

Nykredit A/S’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174K	Buy	+1,308	New	+$118K	﹤0.01%	1091

Other funds holding APGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Nykredit A/S's APGE Position: Q2 2026 in Review

Nykredit A/S opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 1,308 shares worth $174K. The stake represents ﹤0.01% of the portfolio and ranks #1091 among its holdings.

175 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Nykredit A/S held 1,308 shares of Apogee Therapeutics worth $174K as of Q2 2026.
Apogee Therapeutics was a new Nykredit A/S position in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1091 holding.
175 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.